

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By **Shaun Whishaw-Brown**

Scrip Asks...What Does 2022 Hold For Biopharma? Part 3: Technology And Science

Genetic Medicines, RNA Technologies, Protein Degraders Among Hot Areas

17 Feb 2022 | **ANALYSIS**

by **Eleanor Malone** | @ScripEleanor | eleanor.malone@informa.com

Carlo Russo, chief medical officer and head of development at Genenta Science srl, and **Mark Gergen**, CEO at Poseida Therapeutics, Inc., both highlighted manufacturing techniques as areas likely to see improvement in the cell and gene therapy space in 2022.

“The complexity and costs associated in manufacturing cell and gene therapy products has historically significantly limited the growth of the entire space,” commented Russo. “One of the positive outcomes derived from the COVID pandemic is the renewed interest and the associated infusion of capital in development of sophisticated manufacturing processes and analytical technologies to produce biological products. In the not-too-distant future cell and gene products will become more affordable and more easily scalable which in turn will allow the treatment of large patient populations.”

“I believe we will see a continued migration from older viral-based technologies in both cell therapy and gene therapy to better options,” said Gergen. “That shift toward new technologies and non-viral approaches will accelerate as some of these new methods begin to demonstrate the potential for greater safety, efficacy and durability for patients.”